Phase I/II Study of Anti-CTLA-4 Monoclonal Antibody (MDX-010) in B-cell Non-Hodgkin's Lymphoma
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Ipilimumab (Primary)
- Indications B-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 21 Apr 2013 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 02 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Sep 2008 Status changed from suspended to active, no longer recruiting.